Floatz logo

PREDNISONE TABLETS

Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Atezolizumab
Ariceum Therapeutics GmbH
Phase 2B
Durvalumab
Ariceum Therapeutics GmbH
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

PREDNISONE TABLETS is also rated in:

Recurrent Adult T-cell Leukemia/LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →